Clinical Data Confirm Benefits of Morphic Medical’s Obesity Treatment

Morphic Medical is sharing new study results supporting the benefits of its RESET duodenal-jejunal bypass liner for patients suffering from obesity and type 2 diabetes.

The new data was derived from a global registry capturing real-world outcomes in 1,298 patients treated with RESET across 37 centers in 12 countries, including NHS hospitals in Birmingham, London, Southampton, Manchester, and Glasgow. It represents the most comprehensive analysis of RESET in routine clinical practice to date, according to the company. RESET is an incision-free, endoscopic device designed to target the underlying cause of obesity and type 2 diabetes.

“This comprehensive analysis provides crucial evidence for optimizing RESET treatment protocols,” stated Professor Ricardo Cohen, president of the International Federation for the Surgery of Obesity and Metabolic Disorders IFSO. “The data will inform clinical guidelines and help practitioners worldwide deliver more effective, safer care to patients with obesity and type 2 diabetes. It represents a significant step forward in evidence-based endoscopic therapy.”

The findings confirm that RESET delivers substantial and durable benefits:

• Patients lost an average of 18.9% of their total body weight
• Blood sugar levels—as measured by HbA1c, the standard test for long-term glucose control—fell by 1.3%, with the greatest improvements seen in patients starting at higher levels
• Benefits were durable, with 77% of patients maintaining improvement three years after RESET was removed
• The new research-driven, nine-month treatment approach delivers all of the benefits of weight loss and reduction in blood sugar, with fewer complications than the 12-month approach

“I am delighted by these results, which show that RESET delivers nearly 19% weight loss and meaningful improvements in blood sugar control,” Morphic Medical President/CEO Mike Gutteridge commented. “Unlike drug-based therapies, these benefits have been shown to last for years even after treatment has ended. With outcomes achieved in just nine months and with fewer risks, RESET is becoming an increasingly important option for people living with obesity and type 2 diabetes, as well as for governments worldwide tackling these global epidemics.”

RESET recently received CE Mark approval, enabling its commercial launch in the European Union and other geographies that recognize CE marking. A rollout in Germany and the United Kingdom is expected soon. RESET has also been endorsed in the latest clinical guidelines for obesity treatment by both the European Society for Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE).

“RESET is a 60cm impermeable sleeve implanted into the first part of the small intestine. It mimics some of the physiological effects of gastric bypass surgery without any surgery being required, boosting GLP-1, reducing insulin resistance and improving blood sugar and weight control,” said Dr. Bob Ryder, a consultant diabetologist at the Sandwell and West Birmingham NHS Trust. “t offers a less invasive option for people with type 2 diabetes and obesity who haven’t responded sufficiently to medications. The data suggest that nine months is the optimum time to leave RESET before it is removed again with an endoscopy procedure.”

RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.

Founded in 2003, Morphic Medical is headquartered in Boston.

IFSO is a scientific organization that brings together surgeons and health professionals involved in treating severe obesity. It has 76 official member societies, as well as individual members from countries that have not yet formed a national association. One of IFSO’s main activities is its annual World Congress, which provides a forum to exchange knowledge on surgical treatment of severe obesity, to present new techniques, research and concepts, and to connect with experts in the field. IFSO has also produced a number of guidelines and statements on severe obesity and its treatment, and is committed to creating a system for accrediting individual surgeons and bariatric centers worldwide.